flux Healthtech Limited, a Mumbai-based company specializing in healthcare contract manufacturing, is launching its Initial Public Offering (IPO) from June 18 to June 20, 2025. The company is a reputed Contract Development and Manufacturing Organization (CDMO), established in 2020, providing specialized manufacturing solutions across nutraceuticals, cosmetics, ayurvedic, homecare, and veterinary food sectors.

IPO Details

The Influx Healthtech IPO is a Book Built Issue with a total size of ₹58.57 crores, comprising:

• A Fresh Issue of 50.00 lakh shares worth ₹48.00 crores.

• An Offer for Sale (OFS) of 11.00 lakh shares totaling ₹10.57 crores.

The IPO's price band is fixed between ₹91 and ₹96 per equity share. At the upper band price, the company's market capitalization will be approximately ₹222.24 crores.

The IPO is scheduled for listing on the NSE SME platform with the tentative listing date around June 25, 2025. The allotment is expected by June 23, 2025.

Investment Size and Eligibility

• The lot size for the IPO is 1,200 shares.

• Retail investors need to invest a minimum of ₹1,15,200 (1 lot).

• High Net Worth Individuals (HNIs) must apply for at least 2 lots, investing a minimum of ₹2,30,400.

Management and Market Makers

• The IPO is managed by RAREVER FINANCIAL ADVISORS PRIVATE LIMITED as the Book Running Lead Manager.

• The registrar is MAASHITLA SECURITIES PRIVATE LIMITED.

• R.K. Stockholding Private Limited is the designated Market Maker for this IPO.

Grey Market Premium (GMP) and Listing Outlook

The Grey Market Premium for the IPO currently stands at approximately ₹11, indicating an expected listing price around ₹107, or a potential listing gain of 10.56% over the upper price band of ₹96.

However, GMP reflects unregulated market speculation and should be considered informational only.

Anchor Investors

Influx Healthtech raised ₹16.66 crores from Anchor Investors, who purchased 17.36 lakh shares at the upper price band of ₹96. These anchor allocations were from the Qualified Institutional Buyers (QIBs) quota and represent institutional confidence ahead of the IPO subscription.

Financial Performance

The company’s financial performance shows steady growth across key metrics:

Key Financial Ratios

• Pre-issue EPS (FY24): ₹7.36

• Post-issue EPS (FY24): ₹5.77

• Pre-issue P/E: 13.04x

• Post-issue P/E: 16.63x

• Industry P/E: 29x

• ROCE (FY24): 49.17%

• ROE (FY24): 36.98%

• RoNW (FY24): 36.98%

These figures indicate a fairly priced IPO relative to industry standards.

Use of IPO Proceeds

The company plans to deploy the net proceeds toward:

1. ₹22.60 crores for capital expenditure to set up a manufacturing facility for the Nutraceutical Division.

2. ₹11.59 crores for a manufacturing facility for the Veterinary Food Division.

3. ₹2.76 crores to purchase machinery for the Homecare and Cosmetic Division.

4. Remaining funds for general corporate purposes.

Promoter Background

The company is promoted by Mr. Munir Abdul Ganee Chandniwala with over 22 years of experience in nutraceuticals, cosmetics, ayurvedic, and homecare industries, alongside Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala, who bring significant experience in packaging materials and pharmaceuticals respectively.

IPO Allotment Status: How to Check Online

Investors can verify their IPO allotment status from June 23, 2025, by:

• Visiting the registrar’s website.

• Selecting Influx Healthtech Limited IPO from the IPO dropdown.

• Entering their application number, PAN, or DP Client ID.

• Submitting the information to view allotment results.

Analyst Recommendation

Given its consistent revenue and profit growth, sound financial ratios, and a 10.56% Grey Market Premium, Influx Healthtech IPO is recommended primarily for risk-tolerant investors seeking potential listing gains.

However, investors should consider the relatively small size of the SME platform and inherent risks associated with emerging companies in the healthcare manufacturing sector.

Disclaimer:
This article is for educational and informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and consultation with SEBI-registered advisors. Market conditions are volatile and subject to change. Neither the author nor the platform is responsible for losses arising from use of this information.

The Upcoming IPOs in this week and coming weeks are Aakaar Medical Technologies, Safe Enterprises Retail Fixtures, Globe Civil Projects, Sambhav Steel Tubes, Ellenbarrie Indutrial Gases, Kalpataru, HDB Financials, AJC Jewel, ArisInfra Solutions, Influx Healthtech, Mayasheel Ventures.

The Current active IPO are  Eppeltone Engineers, Oswal Pumps, Patil Automation, Samay Projects Services, Aten Papers.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.